

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61L 27/02, 27/04, 27/10, 27/44</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/64505</b> <b>(43) International Publication Date:</b> 2 November 2000 (02.11.00)
<b>(21) International Application Number:</b> PCT/US00/11744 <b>(22) International Filing Date:</b> 27 April 2000 (27.04.00)  <b>(30) Priority Data:</b> 09/300,687                      27 April 1999 (27.04.99)                      US  <b>(71) Applicant:</b> HEALTHSHIELD TECHNOLOGIES L.L.C. [US/US]; Suite 201, 67 Prospect Avenue, West Hartford, CT 06106 (US).  <b>(72) Inventors:</b> BARRY, John, E.; 18 Drake Lane, Derry, NH 03038 (US). TROGOLO, Jeffrey, A.; 228 Commonwealth Avenue, Boston, MA 02116 (US).  <b>(74) Agents:</b> TODARO, John, C.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022-7513 (US) et al.		<b>(81) Designated States:</b> AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ANTIMICROBIAL ORTHOPEDIC IMPLANTS  <b>(57) Abstract</b>  An orthopaedic surgical implant of one or more components having a surface which is to be contacted by body tissue and/or fluid. The surface contains an inorganic antimicrobial agent either incorporated in the material forming a component having the surface or incorporated in a coating, such as of the adhesive or powder spray type, applied to the surface.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ANTIMICROBIAL ORTHOPEDIC IMPLANTS

### Field of the Invention

The invention relates to appliances and devices that are implanted into  
5 the body, such as for orthopedic purposes, and that have antimicrobial properties.

### Background of the Invention

Various devices are often implanted into the body of a human or  
animal for orthopedic purposes such as to strengthen bones, as described in U.S.  
10 Patent 5,443,513; fasten portions of a bone to correct a fracture, such as in U.S. Patent  
4,632,101; and replace joints such as a hip replacement, such as in U.S. Patent  
5,522,904. Other joint replacement applications include the knee and small joints  
such as the fingers.

Such implants can be of metal, of plastic and of composites, such as  
15 carbon fibers in a plastic matrix. The outer exposed surfaces of devices implanted  
into the body come into contact with body tissue and fluids. Since they are foreign in  
nature to the body they pose a site for growth of bacteria and potential infection.  
Therefore, it would be desirable to provide such devices with antimicrobial properties  
so as to reduce the growth of bacteria and risk of infection or to eliminate these  
20 problems.

U.S. Patent 5,756,145 describes the infection problem caused by  
medical implants, such a replacement hip joints, and seeks to solve the problem by  
providing the implant with an antimicrobial coating layer that is covered by one or  
more protective coating layers. The antimicrobial materials considered are basically  
25 of a liquid organic type that require a protective coating layer. This increases the  
complexity of providing the implant with the desired antimicrobial property. Also,  
consideration has to be given to the durability of the coating and the effectiveness of  
the antimicrobial action due to the coating.

### Brief Description of the Invention

The present invention relates to devices implantable into the body, such as for orthopaedic purposes, having antimicrobial properties produced by an inorganic antimicrobial agent. In a preferred embodiment of the invention, the agent is a zeolite. In the case of the device being of metal, the agent is incorporated in a coating that is applied to the surface of the device. With the device being of a polymer (plastic) or a composite of fibers and plastic resin, the resin forming the implant includes the agent. In either case the exposed surface of the implant has an inorganic antimicrobial agent that contacts the body tissue or fluids and kills bacteria.

### Objects of the Invention

It is therefore an object of the invention to provide an orthopaedic implant device that includes an inorganic antimicrobial agent.

A further object is to provide an orthopaedic implant having an inorganic zeolite on its surface to provide antimicrobial action.

Yet another object is to provide an orthopaedic implant of polymeric resin material including an inorganic antimicrobial agent.

An additional object is to provide an orthopaedic implant of metal having a coating on its surface that contains an inorganic antimicrobial agent.

### Brief Description of the Drawings

Other objects and advantages of the present invention will become more apparent upon reference to the following specification and annexed drawings in which:

Fig. 1 is an elevational view of a typical orthopaedic device that is surgically implanted in the body; and

Fig. 2 is a view of the same device with the agent contained in a coating on the device surface.

### Detailed Description of the Invention

Fig. 1 shows one type of a typical hip stem surgical orthopaedic implant device 10 of the type used for hip repair of a human. The implant is described in detail in U.S. Patent 5,443,513, which is hereby incorporated by reference. The  
5 implant described is for illustrative purposes and the present invention is applicable to all types and sizes of implants.

The hip implant 10 includes the stem, or core, 14 of the desired shape. The aforesaid patent describes the stem 14 as illustratively made of a plastic resin material, i.e. short carbon fiber reinforced thermoplastic, such as polyetheretherketone  
10 (PEEK). Implant devices of the desired size and shape can be formed completely of any suitable plastic resin material. The hip stem 14 also can be made of metal, as described below.

One end 19 of the stem is to fit into a cup 20 in a pivotable manner. As is conventional, the cup 20 is usually a composite of a resin core, such as ultra  
15 high molecular weight polyethylene (UHMWPE) or polyethylene, with the core enclosed in a metal shell such as of Ti-6Al-4V. The stem and cup are implanted into the appropriate body parts by the usual surgical techniques.

In accordance with the invention the surfaces of the implant 10 that are to be exposed to body tissue and fluids contains an inorganic antimicrobial agent. In  
20 a preferred embodiment where the stem 14 is of resin, the inorganic antimicrobial agent is incorporated into the resin used to make the stem. The agent does not have to be incorporated into the resin for the cup core since this is not exposed, i.e., it is covered by a metal shell. If the implant, such as the stem 14, is of metal, then its surface is coated with a material containing the inorganic agent.

25 In a typical process for forming the material used to make the devices, a zeolite is used as the antimicrobial agent. Zeolites are often obtained in master batches of pellets of low density polyethylene, polypropylene, UHMWPE or polystyrene, containing 20 wt.% of the zeolite particles. Thus, the pellets of resin containing the zeolite particles can be easily mixed with the resins used as  
30 thermoplastic materials used to make the devices or used in antimicrobial coatings to be applied to devices.

As to implant components of resin, suitable zeolites and methods for incorporating them into the resin are disclosed in U.S. Patents 4,938,955 and 4,906,464. The resins can be those such as polyethylene, polypropylene, polystyrene, polyvinyl chloride, ABS resins, silicones, and mixtures thereof, and others disclosed  
5 in said patents. An UHMWPE is preferred for the implant devices.

For example in making a resin device, such as cup or tibial plateau, the resin pellets containing the zeolite particles are kneaded into the resin for the device. The pellets can be ground to any desired size. Both of these can be, for example, of UHMWPE. The composite of the implant resin and the resin zeolite pellets is then  
10 processed in a conventional manner, such as by injection molding, to form the plastic core for the cup 20 described above or any other device, such as the stem 14 itself. The particles of the agent will be at the exposed surface of the device as formed to be contacted by the body tissue and fluid. Other antimicrobial agents, as described below, are also suitable and would be processed in a manner consistent with the agent  
15 and resin used.

The antimicrobial resin particles are preferably present in a concentration by weight in the resin used to make the implant in an effective amount. This means that there is a sufficient amount of the antimicrobial agent added to or combined with other materials, such as the plastic resin, so as to prevent or inhibit the  
20 growth of bacterial and/or fungal organisms or to kill such organisms. The amount of the agent will vary based on the specific agent used and the material with which it is mixed or added to and upon known factors such as type and use of the device. Environmental factors such as body temperature also should be taken into consideration. In view of this disclosure, it is within the ability of one skilled in the  
25 art to relatively easily determine an effective amount of the antimicrobial agent to be used with each material.

Typical ranges of the zeolite agent particles in the composite resin for the device have been found to be of from 0.01 to 10.0 wt%, more preferably from 0.01 to 8.0 wt%, and most preferably from 0.1 to 5.0 wt%.

30 In one embodiment of the device of U.S. Patent 5,443,513, the core 14 is helically wound with layers of elongated filament fibers embedded in a

thermoplastic polymer resin, sometimes called a prepreg. In accordance with the present invention the agent would be mixed with the thermoplastic polymer resin in the manner described above and be present on the outer surface of the tape which comes into contact with the body tissue, thereby providing the basis for the antimicrobial action.

Configurations suitable for other implants of the general type of Fig. 1 would be made in the same manner. For example, there can be a tibial plateau made of an UHMWPE into which the agent has been incorporated. Here also, the agent would be present at the surface of the device exposed to the body tissue. This would apply to any implant or part that is to be exposed.

Fig. 2 shows the same hip replacement beam type stem 14 and cup 20 as in Fig. 1. Here, the stem is made of a suitable metal, such as Ti-6Al-4V, cobalt chrome alloys such as Co-Cr-Mo, stainless steel and nickel-titanium alloys. The metal shell for the cup 20 can be of the same material. The stem 14, and preferably also the cup 20, of this embodiment has a coating 40 containing the antimicrobial agent over a selected area, usually that which will be exposed in the body. The coating can be formed and applied in several different ways.

In one form, the coating is adhered to the metal surface. Polymer coatings are preferred for this embodiment. The polymers can be of silicone rubber and hydrophilic polymers. The coating can be of, for example, a hydrophilic polymer such as hydrophilic polyurethane or a hydrophilic polymer material having a lubricious property, such as shown in U.S. Patent 5,731,087. Particles containing the antimicrobial agent are mixed with the coating material or pellets of the resin coating material. As with the case of the resin, a concentrate of the liquid is made that can be blended with untreated liquid coating material.

The agent particles comprise by weight of the coating material of between about 0.1% - 100%, more preferably between about 0.1% - 75% and most preferably between about 0.5% - 50.0%. As explained above, an effective amount of the agent is added. The coating 40 with the agent is applied to the outer surface of a metal implant, such as the cup 40, by any suitable technique, such as spraying,

painting or dipping. The agent is available on the surface of the part to come into contact with the body tissue and perform its antimicrobial action.

The coating with the agent also can be applied to the outer surface of a resin implant.

5 Powder coating of a metal implant component with the agent also can be used. The powder coating process usually comprises the basic steps of cleaning the metal, electrostatically spraying the powder and baking. Here, the inorganic antimicrobial agent can be incorporated into the powder, either in the original zeolite particle form that is blended with the powder to be sprayed, or the zeolite particles or  
10 the pellets of resin containing the zeolite particles may be applied in a second step to the surface of a part already powder coated before the baking step. Incorporation of the inorganic antimicrobial into the powder can be accomplished by preparing a master batch concentrate of the pellets containing the agent particles (same ranges as the concentrate above for the resin) which is then blended into the same or a different  
15 polymer used for the spray coating powder to the desired concentration.

The composite of agent containing particles and the spray powder is ground or melt atomized to produce a powder that is used directly or diluted with untreated spray powder used in the conventional powder coating process. The powder is applied in the normal manner.

20 Again, an effective amount of the agent is used. Typically, this is between 0.1 to 30 wt%, preferably 0.5 to 15 wt%, most preferably 1 to 10 wt% of the final powder sprayed on the device.

An alternate method is to combine untreated polymer powder with a solution of an appropriate solvent, with or without a binder, and add the inorganic  
25 antimicrobial particles to coat the inorganic antimicrobial on the polymer powder particles. The solvent is then evaporated and the powder coated with the agent is used in the conventional powder coating process. This ensures that the inorganic antimicrobial is exposed at the surface of the device.

Another method of producing an antimicrobial powder coating is to  
30 apply a powder coating onto the device surface in the conventional manner and then apply a coating of the inorganic antimicrobial particles in a solvent or water. The part



is then dried and baked as in the conventional powder coating process, thus incorporating the inorganic antimicrobial specifically into the near surface of the coating.

Thus, the antimicrobial zeolites are exceptionally suitable under  
5 relevant toxicity and biocompatibility standards for use in the implantable devices.

The preferred antimicrobial agent is an inorganic antimicrobial metal containing composition. A number of metal ions, which are inorganic materials, have been shown to possess antimicrobial activity, including silver, copper, zinc, mercury, tin, lead, bismuth, cadmium, chromium and thallium ions. These antimicrobial metal  
10 ions are believed to exert their effects by disrupting respiration and electron transport systems upon absorption into bacterial or fungal cells. Antimicrobial metal ions of silver, gold, copper and zinc, in particular, are considered safe even for *in vivo* use. Antimicrobial silver ions are particularly useful for *in vivo* use due to the fact that they are not substantially absorbed into the body. That is, if such materials are used they  
15 should pose no hazard.

In one embodiment of the invention, the inorganic antimicrobial metal containing composition is an antimicrobial metal salt. Such salts include silver acetate, silver benzoate, silver carbonate, silver ionate, silver iodide, silver lactate, silver laureate, silver nitrate, silver oxide, silver palpitae, silver protein, and silver  
20 sulfadiazine. Silver nitrate is preferred. These salts are particularly quick acting, as no release from ceramic particles is necessary to function antimicrobially.

Antimicrobial zeolites are preferred. These have been prepared by replacing all or part of the ion-exchangeable ions in zeolite with ammonium ions and antimicrobial metal ions, as described in U.S. Patent Nos. 4,938,958 and 4,911,898.  
25 Such zeolites have been incorporated in antimicrobial resins (as shown in U.S. Patent Nos. 4,938,955 and 4,906,464) and polymer articles (U.S. Patent No. 4,775,585). Polymers including the antimicrobial zeolites have been used to make refrigerators, dish washers, rice cookers, plastic film, chopping boards, vacuum bottles, plastic pails, and garbage containers. Other materials in which antimicrobial zeolites have  
30 been incorporated include flooring, wall paper, cloth, paint, napkins, plastic automobile parts, catheters, bicycles, pens, toys, sand, and concrete. Examples of

such uses are described in U.S. Patents 5,714,445; 5,697,203; 5,562,872; 5,180,585; 5,714,430; and 5,102,401.

Antimicrobial ceramic particles useful with the present invention include zeolites, hydroxy apatite, zirconium phosphates or other ion-exchange  
5 ceramics. Zeolites are preferred, and are described in the preferred embodiments referred to below. Hydroxy apatite particles containing antimicrobial metals are described, e.g., in U.S. Patent No. 5,009,898. Zirconium phosphates containing antimicrobial metals are described, e.g., in U.S. Patent Nos. 5,296,238; 5,441,717; and 5,405,644.

10 Inorganic particles, such as the oxides of titanium, aluminum, zinc and copper, may be coated with a composition which confers antimicrobial properties, for example, by releasing antimicrobial metal ions such as silver ions, which are described, e.g., in U.S. Patent No. 5,180,585. Inorganic soluble glass particles containing antimicrobial metal ions, such as silver, are described, e.g., in U.S. Patent  
15 Nos. 5,766,611 and 5,290,544.

Antimicrobial zeolites are well-known and can be prepared for use in the present invention using known methods. These include the antimicrobial zeolites disclosed, for example, in U.S. Patent Nos. 4,938,958 and 4,911,898.

Either natural zeolites or synthetic zeolites can be used to make the  
20 antimicrobial zeolites used in the present invention. "Zeolite" is an aluminosilicate having a three dimensional skeletal structure that is represented by the formula:  $XM_{2/n}O-Al_2O_3-YSiO_2-ZH_2O$ . M represents an ion-exchangeable ion, generally a monovalent or divalent metal ion, n represents the atomic valency of the (metal) ion, X and Y represent coefficients of metal oxide and silica respectively, and Z represents  
25 the number of water of crystallization. Examples of such zeolites include A-type zeolites, X-type zeolites, Y-type zeolites, T-type zeolites, high-silica zeolites, sodalite, mordenite, analcite, clinoptilolite, chabazite and erionite. The present invention is not restricted to use of these specific zeolites.

The ion-exchange capacities of these zeolites are as follows: A-type  
30 zeolite = 7 meq/g; X-type zeolite = 6.4 meq/g; Y-type zeolite = 5 meq/g; T-type zeolite = 3.4 meq/g; sodalite = 11.5 meq/g; mordenite = 2.6 meq/g; analcite = 5

meq/g; clinoptilolite = 2.6 meq/g; chabazite = 5 meq/g; and erionite = 3.8 meq/g.

These ion-exchange capacities are sufficient for the zeolites to undergo ion-exchange with ammonium and antimicrobial metal ions.

The specific surface area of preferred zeolite particles is preferably at least 150 m<sup>2</sup>/g (anhydrous zeolite as standard) and the SiO<sub>2</sub>/Al<sub>2</sub>O<sub>3</sub> mol ratio in the zeolite composition is preferably less than 14, more preferably less than 11.

The antimicrobial metal ions used in the antimicrobial zeolites should be retained on the zeolite particles through an ion-exchange reaction. Antimicrobial metal ions which are adsorbed or attached without an ion-exchange reaction exhibit a decreased bactericidal effect and their antimicrobial effect is not long-lasting. Nevertheless, it is advantageous for imparting quick antimicrobial action to maintain a sufficient amount of surface adsorbed metal ion.

In the ion-exchange process, the antimicrobial metal ions tend to be converted into their oxides, hydroxides, basic salts etc. either in the micropores or on the surfaces of the zeolite and also tend to deposit there, particularly when the concentration of metal ions in the vicinity of the zeolite surface is high. Such deposition tends to adversely affect the bactericidal properties of ion-exchanged zeolite.

In an embodiment of the antimicrobial zeolites, a relatively low degree of ion exchange is employed to obtain superior bactericidal properties. It is believed to be required that at least a portion of the zeolite particles retain metal ions having bactericidal properties at ion-exchangeable sites of the zeolite in an amount less than the ion-exchange saturation capacity of the zeolite. In one embodiment, the zeolite employed in the present invention retains antimicrobial metal ions in an amount up to 41% of the theoretical ion-exchange capacity of the zeolite. Such ion-exchanged zeolite with a relatively low degree of ion-exchange may be prepared by performing ion-exchange using a metal ion solution having a low concentration as compared with solutions conventionally used for ion exchange.

The antimicrobial metal ion is preferably present in the range of from about 0.1 to 20 wt.% of the zeolite. In one embodiment, the zeolite contains from 0.1 to 20 wt.% of silver ions and from 0.1 to 20 wt.% of copper or zinc ions. Although

ammonium ion can be contained in the zeolite at a concentration of about 20 wt.% or less of the zeolite, it is desirable to limit the content of ammonium ions to from 0.5 to 15 wt.%, preferably 1.5 to 5 wt.%. Weight % described herein is determined for materials dried at temperatures such as 110°C, 250°C or 550°C as this is the temperature employed for the preferred post-manufacturing drying process.

A preferred antimicrobial zeolite is type A zeolite containing either a combination of ion-exchanged silver, zinc, and ammonium or silver and ammonium. One such zeolite is manufactured by Shinagawa, Inc. under the product number AW-10N and consists of 0.6% by weight of silver ion-exchanged in Type A zeolite particles having a diameter of about 2.5 $\mu$ . Another formulation, AJ-10N, consists of about 2% by weight silver ion-exchanged in Type A zeolite particles having a diameter of about 2.5 $\mu$ . Another formulation, AW-80, contains 0.6% by weight of silver ion-exchanged in Type A zeolite particles having a diameter of about 1.0 $\mu$ . Another formulation, AJ-80N, consists of about 2% by weight silver ion-exchanged in Type A zeolite particles having a diameter of about 1.0 $\mu$ . These zeolites preferably contain about between 0.5% and 2.5% by weight of ion-exchanged ammonium. Type AJ10D consists of about 2.5% by weight of silver ion-exchanged in Type A zeolite particles having a diameter of about 1.0 $\mu$ .

The zeolites are often obtained in master batches of low density polyethylene, polypropylene, or polystyrene, containing 20 wt.% of the zeolite. Thus, they can be easily mixed with the resins used as materials for forming a composite resin used to make the device.

The antimicrobial properties of the antimicrobial zeolite particles of the invention may be assayed while in aqueous formulations using conventional assay techniques, including for example determining the minimum growth inhibitory concentration (MIC) with respect to a variety of bacteria, eumycetes and yeast. In such a test, the bacteria listed below may be employed:

*Bacillus cereus varmycoides*;

*Escherichia coli*;

*Pseudomonas aeruginosa*;

*Staphylococcus aureus*;

*Streptococcus faecalis*;  
*Aspergillus niger*;  
*Aureobasidium pullulans*;  
*Chaetomium globosum*;  
5 *Gliocladium virens*;  
*Penicillium funiculosum*;  
*Candida albicans*; and  
*Saccharomyces cerevisiae*.

The assay for determining MIC can be carried out by smearing a  
10 solution containing bacteria for inoculation onto a plate culture medium to which a  
test sample of the encapsulated antimicrobial zeolite particles is added in a particular  
concentration, followed by incubation and culturing of the plate. The MIC is defined  
as a minimum concentration thereof required for inhibiting the growth of each  
bacteria.

15 Safety and biocompatibility tests were conducted on the antimicrobial  
zeolites employed in the invention. ISO 10993-1 procedures were employed. The  
following results were obtained:

20	<b>Cytotoxicity: Non-Toxic</b>
	<b>Acute Systemic Toxicity: Non-Toxic</b>
	<b>Oral Toxicity: Safer than table salt</b>
	<b>Intracutaneous Toxicity: Passed</b>
	<b>Skin Irritation Test: Non-Irritant</b>
	<b>Chronic Toxicity: No Observable Effect</b>
25	<b>In-vitro Hemolysis: Non-Hemolytic</b>
	<b>30-day Muscle Implant Test: Passed</b>
	<b>60-day Muscle Implant Test: Passed</b>
	<b>90-day Muscle Implant Test: Passed</b>
	<b>Ames Mutagenicity Test: Passed</b>
30	<b>Pyrogenicity: Non-Pyrogenic</b>

Thus, the antimicrobial zeolites are exceptionally suitable under relevant toxicity and biocompatibility standards for use in the implantable devices.

An embodiment of the orthopedic implant formed from a resin has the following components:

plastic resin of device	UHMWPE
material of agent	silver zeolite (preferably type AJ10D)
wt.% of agent in composite	5.0%
size of the agent particles	1.0 micron

A typical embodiment of the metal orthopedic implant that is coated is

metal of device	Ti-6Al-4V
material of agent	silver zeolite (preferably type AJ10N)
coating material	urethane
wt.% of agent in coating	30.0% of coating
size of the agent particles	1.0 micron

A typical embodiment of the powder coated orthopedic implant is

metal of device	Ti-6Al-4V
material of agent	silver zeolite (preferably type AJ10N)
powder coating material	silica
wt.% of agent in powder	10.0%
size of the agent particles	1.0 micron

Specific features of the invention are shown in one or more of the drawings for convenience only, as each feature may be combined with other features in accordance with the invention. Alternative embodiments will be recognized by those skilled in the art and are intended to be included within the scope of the claims.

While preferred embodiments of the invention have been described in the foregoing examples, it will be understood by one skilled in the art that various changes and modifications may be made therein without departing from the spirit and the scope of the invention. All patent applications, patents, patent publications, and  
5 literature references cited in this specification are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present description, including definitions, is intended to control. Accordingly, the above description should be construed as illustrating and not limiting the scope of the invention. All such obvious changes and modifications are within the patented scope of the appended claims.

## We Claim:

1                   1. An orthopedic surgical implant comprising at least one component  
2     having a surface which is to be contacted by body tissue or fluid, said surface containing  
3     antimicrobial zeolite particles.

1                   2. The orthopedic surgical implant of claim 2, wherein said zeolite  
2     particles contain silver cations as the active ingredient.

1                   3. The orthopedic surgical implant of claim 2, wherein said zeolite  
2     particles contain antimicrobial metal ions retained on the zeolite particles.

1                   4. The orthopedic surgical implant of claim 1 wherein said surface  
2     comprises a plastic resin containing said antimicrobial zeolite particles.

1                   5. The orthopedic surgical implant of claim 4 wherein said plastic  
2     resin is UHMWPE.

1                   6. The orthopedic surgical implant of claim 4 wherein said inorganic  
2     antimicrobial zeolite particles comprise from 0.25% to 10.0% by total weight of said  
3     plastic resin.

1                   7. The orthopedic surgical implant of claim 1 wherein said at least one  
2     component comprises a metal.

1                   8. The orthopedic surgical implant of claim 1 having first and second  
2     components, said first component comprising a plastic resin incorporating said  
3     antimicrobial zeolite particles to form said surface, and said second component having  
4     a coating applied thereto that contains said antimicrobial zeolite particles.

1                   9. The orthopedic surgical implant of claim 8 wherein said second  
2     component comprises a metal to which said coating is adhered.



1                   10. An orthopedic surgical implant as in claim 1 wherein said  
2 antimicrobial zeolite particles are from 0.25 to 10.0 microns.

1                   11. An orthopedic surgical implant as in claim 1 wherein said at least  
2 one component is of metal and said agent is in a coating adhered to said at least one  
3 component and contains said antimicrobial zeolite particles.

1                   12. An orthopedic surgical implant comprising at least one component  
2 having a surface which is to be contacted by body tissue or fluid, said surface containing  
3 an inorganic antimicrobial agent.

1                   13. The orthopedic surgical implant of claim 12, wherein said  
2 inorganic antimicrobial agent comprises inorganic particles containing silver cations as  
3 an active ingredient.

1                   14. The orthopedic surgical implant of claim 12, wherein said particles  
2 are ceramic particles.

1                   15. The orthopedic surgical implant of claim 1 wherein the  
2 antimicrobial metal ions are selected from the group consisting of gold, silver, copper and  
3 zinc ions.

1                   16. The orthopedic surgical implant of claim 1 wherein the metal  
2 cations are present on the zeolite as a result of an ion-exchange process.

1                   17. The orthopedic surgical implant of claim 12 wherein the  
2 antimicrobial metal ions are selected from the group consisting of gold, silver, copper and  
3 zinc ions.

1                   18. The orthopedic surgical implant of claim 12 wherein the



2 metal cations are present on the ion-exchange ceramic particles as a result of an ion-  
3 exchange process.

1 19. The orthopedic surgical implant of claim 12 wherein said at  
2 least one component is of metal and said surface comprises a coating adhered to said at  
3 least one component and containing said antimicrobial ion-exchange ceramic particles.

1 20. The orthopedic surgical implant of claim 12 wherein said  
2 surface comprises a plastic resin containing said antimicrobial ion-exchange ceramic  
3 particles.

1 21. The orthopedic surgical implant of claim 12 wherein said at least  
2 one component is of metal.

1/1



# INTERNATIONAL SEARCH REPORT

Int. l. Application No  
PCT/US 00/11744

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61L27/02 A61L27/04 A61L27/10 A61L27/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61L G02C G02B C01B C08K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 31709 A (UNIV NEW YORK) 4 September 1997 (1997-09-04) page 9, line 18 - line 20 page 15, line 34 claims	1-4,7-21
X	EP 0 781 566 A (TOYO BOSEKI) 2 July 1997 (1997-07-02)  claims 1-3,6-13,16	1-4,7-9, 11-15, 17,21
X	WO 99 07326 A (FRIEDMAN SHIMON ;UNIV TORONTO (CA); SANTERRE JOSEPH PAUL (CA)) 18 February 1999 (1999-02-18) claims	1-3,7, 11-19,21
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

24 August 2000

Date of mailing of the international search report

31/08/2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Thornton, S

# INTERNATIONAL SEARCH REPORT

Int. l. Application No  
PCT/US 00/11744

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 640 661 A (SHINETSU CHEMICAL CO) 1 March 1995 (1995-03-01) page 4, line 43 - line 48 claims	1-21
E	WO 00 30567 A (HEALTHSHIELD TECHNOLOGIES LLC) 2 June 2000 (2000-06-02) claims	1-21
E	WO 00 30697 A (HEALTHSHIELD TECHNOLOGIES LLC) 2 June 2000 (2000-06-02) claims	1-21

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. National Application No

PCT/US 00/11744

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9731709	A	04-09-1997	AU 2061297 A		16-09-1997
			EP 0883438 A		16-12-1998
EP 0781566	A	02-07-1997	JP 9176379 A		08-07-1997
			JP 9187501 A		22-07-1997
			JP 9187502 A		22-07-1997
			JP 10151191 A		09-06-1998
			JP 10158432 A		16-06-1998
			US 5783570 A		21-07-1998
WO 9907326	A	18-02-1999	AU 8846398 A		01-03-1999
EP 0640661	A	01-03-1995	JP 7062242 A		07-03-1995
			DE 69421351 D		02-12-1999
			DE 69421351 T		30-03-2000
			US 5466726 A		14-11-1995
WO 0030567	A	02-06-2000	NONE		
WO 0030697	A	02-06-2000	NONE		